Alkermes eyes orexin ADHD drug as potential 'company changer'
Following Takeda's approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has reported pioneering ADHD data that looks to take the hyped drug class beyond sleep disorders.